This article presents the revised consensus criteria for the diagnosis of frontotemporal
dysfunction in amyotrophic lateral sclerosis (ALS) based on an international research …

Many aspects of cognition and behaviour are regulated by noradrenergic projections to the
forebrain originating from the locus coeruleus, acting through alpha and beta …

Objective To revise the 1999 Airlie House consensus guidelines for the design and
implementation of preclinical therapeutic studies and clinical trials in amyotrophic lateral …

It is now well recognized that, in addition to motor impairment, amyotrophic lateral sclerosis
(ALS) may cause extra-motor clinical signs and symptoms. These can include the alteration …

Patients with motor neuron diseases may present to primary care clinic or may be initially
encountered in the inpatient setting. Timely diagnosis of these conditions is a key factor in …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a rapid course,
characterized by motor neuron dysfunction, leading to progressive disability and death. This …

Background Selection of appropriate trial endpoints and outcome measures is particularly
important in rare disease and rapidly progressing disease such as amyotrophic lateral …

The historical view that Amyotrophic Lateral Sclerosis (ALS) as a pure motor disorder has
been increasingly challenged by the discovery of cognitive and behavioral changes in the …

Cognitive dysfunction is an important non-motor symptom in amyotrophic lateral sclerosis
(ALS) that has a negative impact on survival and caregiver burden. It shows a wide spectrum …

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, leading to
progressive paralysis, dysarthria, dysphagia, and respiratory disabilities. Therapy is mostly …